• Corpus ID: 26616448

Metoclopramide : A Template for Drug Discovery

  title={Metoclopramide : A Template for Drug Discovery},
  author={Gareth John Sanger},
Metoclopramide was described in 1964 as an anti-emetic drug and stimulant of gastrointestinal motility. Dopamine D2 receptor antagonism explained the anti-emetic activity and was suggested to stimulate gastrointestinal motility. An important use of metoclopramide and other D2 receptor antagonists is to inhibit emesis caused by anticancer chemo radiotherapy. However, the use of new platinum-based anti-cancer drugs led to debilitating emesis, lasting for days and sometimes leading to refusal of… 
A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research
The repurposing of different drugs for treatment of nausea and vomiting is examined, particularly during palliative care, and also the challenges in identifying novel anti-emetic drugs, particularly for Treatment of nausea as compared to vomiting.
Perioperative pain management in COVID-19 patients: Considerations and recommendations by the Saudi Anesthesia Society (SAS) and Saudi Society of Pain Medicine (SSPM)
An up-to-date guide for anesthesia providers to help them manage perioperative pain in COVID-19 patients presenting for surgery is formulated.


Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.
A fundamental role for 5-HT3 receptors in the mechanisms mediating severely emetogenic cancer treatment therapies is discussed in terms of a fundamental role to prevent emesis evoked by cytotoxic drugs or by total body irradiation.
Management of highly emetogenic chemotherapy
  • D. Warr
  • Medicine, Biology
    Current opinion in oncology
  • 2012
Clinical data suggest that, although classified as highly emetogenic, palonosetron may provide very good control of emesis for CHOP and ABVD, and major guideline groups recommend a combination of a 5-HT3 receptor antagonist, dexamethasone and aprepitant (‘triple therapy’).
Metoclopramide: A Review of its Pharmacological Properties and Clinical Use
Pharmacodynamic studies in man and in a variety of experimental animals have established that metoclopramide, after oral or intravenous administration, rapidly affects the motility of the gastro-intestinal tract, and is effective in preventing apomorphine-induced vomiting in man.
Nausea and the quest for the perfect anti-emetic.
Use of ondansetron in palliative medicine.
Translating 5‐HT4 receptor pharmacology
  • G. Sanger
  • Biology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2009
The progress of this compound for treatment of chronic constipation, as well as competitor molecules such as ATI‐7505 and TD‐5108, will now be followed with interest as each attempts to differentiate themselves from each other.
Metoclopramide. An updated review of its pharmacological properties and clinical use.
Metoclopramide has been confirmed as an effective drug in treating and preventing various types of vomiting and as a useful agent in oesophageal reflux disease, gastroparesis, dyspepsia, and in a variety of functional gastrointestinal disorders.
Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
It has been suggested that the serotonergic (5‐HT4) component of some antidopaminergic prokinetics may enhance their therapeutic efficacy in gastrointestinal disorders, such as functional dyspepsia and diabetic gastroparesis.
5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis